In an era where access to effective obesity care remains mired in controversy over medication costs and payer reluctance, a promising model is gaining...
There may be a dose-related effect of omega-3 fatty acids on atrial fibrillation risk. In high doses there appeared to be an increase in risk for atrial fibrillation in the omega-3 groups (versus control) in both trials.
Gabor Maté’s issues are with evidence, not the West and with public health, not medicine, but who takes him seriously? Lots of otherwise smart people seem to…or maybe not.